Skip Navigation
 

SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE

Therapeutics Translation Core

The process of developing a successful commercial drug or medical device involves several sequential steps: discovery/prototyping, pre-clinical testing, Phase I – Phase III clinical trials, FDA approval, and marketing of the product, in addition to developing an intellectual property strategy. This process is long and expensive and involves a complex interaction between academia, industry, investors, and regulatory agencies.

With strategic partnerships on campus, the Therapeutics Translation Core (TTC) aims to accelerate academic innovations into marketed products and to educate MUSC faculty, staff, students and community members about therapeutic development and entrepreneurial processes. TTC initiatives include:

  • Technology Development Awards (gap funding) to advance early stage technologies with high commercial potential and a defined intellectual property strategy to the next development milestone
  • Consultative services to MUSC startup companies applying for SBIR or STTR grants
  • Developing an online entrepreneurial curriculum covering intellectual property, regulatory pathways, and entrepreneurial topics to foster a fundamental understanding of these topics among the MUSC community
 


Technology Development Awards

In partnership with the MUSC Foundation for Research Development (FRD), the TTC offers Technology Development Awards, which provide funding of up to $25,000 to advance innovative and clinically relevant technologies. The awards support short-term (six month) studies designed to improve the commercial value of the technologies by strengthening the intellectual property (IP) and moving technologies further down the development pathway, thus increasing the partnerships and licensing opportunities with pharmaceutical, biotechnology, and medical device companies.

The primary objective of the gap funding awards is to support projects that have a high chance of being commercialized, but that are not likely to get there without gap funding. Funds are intended to advance projects to the next developmental milestone by enabling investigators to conduct additional experiments, such as those that optimize compounds, conduct toxicology studies, define a translational biomarker, prototype a device, or build/validate a software program.

Previous Recipients

Nancy DeMore, MD, FACS

 Project:
 Development of a Titanium Clip Metal Detector to Aid Breast Localization Surgery

December 2016

Michael J. Yost, PhD

Project:
Engineering Smart wound device for closure of difficult wounds

March 2016

James Chou, PhD

Project:
Determination of PK/PD Properties of Novel Compounds to Treat Parkinson’s Disease

Nathan Dolloff, PhD

Project:
Generation of Novel Derivatives of Compound E61 for the Treatment of Refractory Multiple Myeloma

December 2015

Nancy DeMore, MD, FACS

Project:
Characterization of Dose-Response Relationships of a Novel Monoclonal Antibody for Melanoma Treatment

Jennifer Wu, PhD

Project:
Development of a Fusion Molecule to Advance a Proprietary Cancer Immunotherapeutic Technology

 



Consultative Services

The TTC provides support to the FRD to assist faculty startups with SBIR or STTR applications that include a subcontract back to the university. The TTC provides funds to support FRD-hired consultants to provide input on a variety of topics, such as grant structure, regulatory path, market analysis, among others.

Faculty, staff and students interested in starting a company and/or applying for an SBIR or STTR grant may request a consultation via SPARCRequest or may contact FRD directly.

 



Entrepreneurial Certificate Program

In collaboration with the College of Graduate Studies, FRD, and the Medical University Hospital Innovation Center (MUHIC), the TTC is developing a certificate program in entrepreneurship that will be structured in modules and offered widely via a web-based portal. The modules will cover policies and topics important to business development, intellectual property, agreements, and regulatory oversight. The program has a targeted completion date of Fall 2016.
 



Leadership
 



Jesse Goodwin, PhD
Director
Vice President for Development
Zucker Institute for Applied Neuroscience
SCTR Technology Development Officer
goodwijs@musc.edu

Mark D. Hankins, JD
Co-Director
Director of Licensing
MUSC Foundation for Research Development
goodwijs@musc.edu


Contact

Ford Simmons, MLIS
Program Coordinator
(843) 792-2994
simmonwi@musc.edu
 

 
 
 

© 2017 Medical University of South Carolina | Disclaimer